Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Pan-Asia Index Rebalances/ Events/ Delta One

Index Rebalance

<p>The KRX has announced the list of inclusions and exclusions to the KOSDAQ150 Index today. The rebalance is effective after the close of trading on 10 December.</p><p>There are 17 inclusions and 17 exclusions in the December 2020 review with an estimated one-way turnover of 7.71%.</p><p>The inclusions and exclusions are:</p><table class="table table-striped">
<colgroup><col span="4"></colgroup>
<tbody>
<tr>
<td colspan="2" style="text-align: center; width: 96pt;"><h3>Additions</h3></td>
<td colspan="2" style="text-align: center; width: 96pt;"><h3>Deletions</h3></td>
</tr>
<tr>
<td style="text-align: center;"><strong>Code</strong></td>
<td style="text-align: center;"><strong>Name</strong></td>
<td style="text-align: center;"><strong>Code</strong></td>
<td style="text-align: center;"><strong>Name</strong></td>
</tr>
<tr>
<td>034950.KQ</td>
<td>Korea Ratings Corp</td>
<td>014620.KQ</td>
<td>Sung Kwang Bend Co Ltd</td>
</tr>
<tr>
<td>078600.KQ</td>
<td>Daejoo Electronic Materials Co Ltd</td>
<td>015750.KQ</td>
<td>Sungwoo Hitech Co Ltd</td>
</tr>
<tr>
<td>089980.KQ</td>
<td>Sang-A Frontec Co Ltd</td>
<td>023160.KQ</td>
<td>TK Corp</td>
</tr>
<tr>
<td>092190.KQ</td>
<td>Seoul Viosys Co Ltd</td>
<td>039840.KQ</td>
<td>Dio Corp</td>
</tr>
<tr>
<td>100130.KQ</td>
<td>Dongkuk Structures &amp; Construction Co Ltd</td>
<td>041190.KQ</td>
<td>Woori Technology Investment Co Ltd</td>
</tr>
<tr>
<td>101490.KQ</td>
<td>S&amp;S Tech Corp</td>
<td>041830.KQ</td>
<td>InBody Co Ltd</td>
</tr>
<tr>
<td>131370.KQ</td>
<td>Rsupport Co Ltd</td>
<td>043150.KQ</td>
<td>Value Added Technology Co Ltd</td>
</tr>
<tr>
<td>137400.KQ</td>
<td>People &amp; Technology Inc</td>
<td>047310.KQ</td>
<td>Power Logics</td>
</tr>
<tr>
<td>194700.KQ</td>
<td>Novarex Co Ltd</td>
<td>049950.KQ</td>
<td>MeereCompany Inc</td>
</tr>
<tr>
<td>204270.KQ</td>
<td>JNTC Co Ltd</td>
<td>051500.KQ</td>
<td>CJ Freshway Corp</td>
</tr>
<tr>
<td>222080.KQ</td>
<td>Creative &amp; Innovative System Corp</td>
<td>063570.KQ</td>
<td>Nice Total Cash Management Co Ltd</td>
</tr>
<tr>
<td>235980.KQ</td>
<td>MedPacto Inc</td>
<td>080160.KQ</td>
<td>Modetour Network Inc</td>
</tr>
<tr>
<td>290510.KQ</td>
<td>KoreaCenter Co Ltd</td>
<td>084110.KQ</td>
<td>Huons Global Co Ltd</td>
</tr>
<tr>
<td>290650.KQ</td>
<td>L&amp;C Bio Co Ltd</td>
<td>089600.KQ</td>
<td>Nasmedia Co Ltd</td>
</tr>
<tr>
<td>293490.KQ</td>
<td>Kakao Games Corp</td>
<td>115960.KQ</td>
<td>Yonwoo Co Ltd</td>
</tr>
<tr>
<td>294140.KQ</td>
<td>Lemon Co Ltd</td>
<td>228760.KQ</td>
<td>Genomictree Inc</td>
</tr>
<tr>
<td>357780.KQ</td>
<td>SoulBrain Co Ltd</td>
<td>282880.KQ</td>
<td>CowinTech Co Ltd</td>
</tr>
</tbody>
</table><p>There are 11 trading days to implementation. There are 2 additions that have more than 3 days of ADV to trade while there are 9 deletions that have more than 3 days of ADV to trade. Things could get interesting over the next couple of weeks.</p>

The KRX has announced the list of inclusions and exclusions to the KOSDAQ150 Index today. The rebalance is effective after the close of trading on 10 December.There are 17 inclusions and 17 exclusions in the December 2020 review with an estimated one-way turnover of 7.71%.The inclusions and exclusions are:



Additions
Deletions


Code
Name
Code
Name


034950.KQ
Korea Ratings Corp
014620.KQ
Sung Kwang Bend Co Ltd


078600.KQ
Daejoo Electronic Materials Co Ltd
015750.KQ
Sungwoo Hitech Co Ltd


089980.KQ
Sang-A Frontec Co Ltd
023160.KQ
TK Corp


092190.KQ
Seoul Viosys Co Ltd
039840.KQ
Dio Corp


100130.KQ
Dongkuk Structures &amp; Construction Co Ltd
041190.KQ
Woori Technology Investment Co Ltd


101490.KQ
S&amp;S Tech Corp
041830.KQ
InBody Co Ltd


131370.KQ
Rsupport Co Ltd
043150.KQ
Value Added Technology Co Ltd


137400.KQ
People &amp; Technology Inc
047310.KQ
Power Logics


194700.KQ
Novarex Co Ltd
049950.KQ
MeereCompany Inc


204270.KQ
JNTC Co Ltd
051500.KQ
CJ Freshway Corp


222080.KQ
Creative &amp; Innovative System Corp
063570.KQ
Nice Total Cash Management Co Ltd


235980.KQ
MedPacto Inc
080160.KQ
Modetour Network Inc


290510.KQ
KoreaCenter Co Ltd
084110.KQ
Huons Global Co Ltd


290650.KQ
L&amp;C Bio Co Ltd
089600.KQ
Nasmedia Co Ltd


293490.KQ
Kakao Games Corp
115960.KQ
Yonwoo Co Ltd


294140.KQ
Lemon Co Ltd
228760.KQ
Genomictree Inc


357780.KQ
SoulBrain Co Ltd
282880.KQ
CowinTech Co Ltd


There are 11 trading days to implementation. There are 2 additions that have more than 3 days of ADV to trade while there are 9 deletions that have more than 3 days of ADV to trade. Things could get interesting over the next couple of weeks.

KOSDAQ150 Index Rebalance: Lots of Changes, Big Turnover, High Impact

Global Special Situations & Strategy, SR Services Ltd

David Lepper

Global Special Situations & Strategy

SR Services Ltd

SR Services provides Strategic Knowledge and Solutions services for Family Offices and Corporate Business. 

We deliver this via advisory services, strategic planning, opportunity analysis/sourcing, as well as solution implementation. 

Whilst, we create intellectual discipline and operational leverage for your projects or daily activities, our ultimate objective is to empower whilst enhancing your decision making. 

Strategic Knowledge and Solutions

Cross Asset Strategy

<p>Growth as an investment style has remained prominent over the COVID-19 period, reinforcing its decade long dominance over the value. The key question remains:  with earnings and value set to be a key theme over H2 2020 when exactly is the value style expected to reverse its underperformance trend? Our data suggest a greater than 66% chance of reversal shortly. As the value style reversal looks increasingly assured, exposure to GARP style investing and the underlying stocks are set to become even more important as we move into the second half of 2020. We highlight 17 stocks who fit the criteria in Q2 2020.</p>

Growth as an investment style has remained prominent over the COVID-19 period, reinforcing its decade long dominance over the value. The key question remains:  with earnings and value set to be a key theme over H2 2020 when exactly is the value style expected to reverse its underperformance trend? Our data suggest a greater than 66% chance of reversal shortly. As the value style reversal looks increasingly assured, exposure to GARP style investing and the underlying stocks are set to become even more important as we move into the second half of 2020. We highlight 17 stocks who fit the criteria in Q2 2020.

Screening the Silk Road: Q2-2020 Small-Mid Cap GARP (Zulu Warrior Screening)

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

MSCI Emerging Markets Index / Technical Analysis

<p>EM equities remain long-term leadership despite giving up some ground over the last month to developed markets. Given the intact relative strength uptrend, we reiterate our overweight EM recommendation. Energy and Health Care stocks are outperforming and remain attractive. Technology is consolidating and we would use recent weakness as a buying opportunity. Today’s report includes a wide variety of bottom-up recommendations, spanning most sectors and all market capitalizations.</p>

EM equities remain long-term leadership despite giving up some ground over the last month to developed markets. Given the intact relative strength uptrend, we reiterate our overweight EM recommendation. Energy and Health Care stocks are outperforming and remain attractive. Technology is consolidating and we would use recent weakness as a buying opportunity. Today’s report includes a wide variety of bottom-up recommendations, spanning most sectors and all market capitalizations.

EM Strategy: Overweight Technology, Energy, and Health Care.

Frontier and emerging markets (Vietnam)

Dylan Waller

Nomadic Equity

Thematic (Sector/Industry)

<p><strong>Introduction to Medisetter</strong></p><p>I had the pleasure of interviewing Anirban Lahiri of Medisetter to discuss some of the opportunities present in Asia's healthcare industry. Medisetter is an international online medical travel search and bookings platform offering a one-stop-shop medical travel booking and planning service. Prospective patients can search and compare hospitals and clinics across different countries, receive price quotes, book appointments and also book accommodation, translators and…</p>

Introduction to MedisetterI had the pleasure of interviewing Anirban Lahiri of Medisetter to discuss some of the opportunities present in Asia's healthcare industry. Medisetter is an international online medical travel search and bookings platform offering a one-stop-shop medical travel booking and planning service. Prospective patients can search and compare hospitals and clinics across different countries, receive price quotes, book appointments and also book accommodation, translators and…

MediSetter Interview: Insight on Opportunities in Asia's Healthcare Industry

Korea / Special Situations, Clepsydra Capital

Sanghyun Park

Korea / Special Situations

<p>SillaJen Biotherapeutics (established in 2006) is indeed a rare breed in Korean pharmaceutical world. It is not a generic drug maker. It is not a biosimilar maker either. It makes new biomedical products. A majority of Korea's pharmaceutical makers are still generic drug makers. The likes of Celltrion and Samsung Bioepis have emerged as a biosimilar maker. But they are still a few. Biomedical makers are even rarer. Hanmi Pharmaceutical is one of these rare breeds. Now, another biomedical maker…</p>

SillaJen Biotherapeutics (established in 2006) is indeed a rare breed in Korean pharmaceutical world. It is not a generic drug maker. It is not a biosimilar maker either. It makes new biomedical products. A majority of Korea's pharmaceutical makers are still generic drug makers. The likes of Celltrion and Samsung Bioepis have emerged as a biosimilar maker. But they are still a few. Biomedical makers are even rarer. Hanmi Pharmaceutical is one of these rare breeds. Now, another biomedical maker…

SillaJen's December IPO: Valuation, Growth Expectation and IPO Timing

South Korea

Value Added Technology Co., Ltd. develops, manufactures, and engages in sales of digital radiography medical equipments for dental clinics.  The Company also supplies digital sensor for X-ray equipments.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Value Added Technologies (043150 KS)

KOSDAQ150 Index Rebalance: Lots of Changes, Big Turnover, High Impact

There are 17 changes to the KOSDAQ150 index and the turnover is estimated at 7.71%. There are a lot of stocks that have over 3 days of ADV to trade...

Brian Freitas

Screening the Silk Road: Q2-2020 Small-Mid Cap GARP (Zulu Warrior Screening)

Growth as an investment style has remained prominent over the COVID-19 period, reinforcing its decade long dominance over the value. The key...

David Lepper

EM Strategy: Overweight Technology, Energy, and Health Care.

EM equities remain long-term leadership despite giving up some ground over the last month to developed markets. Given the intact relative strength...

Vermilion Research

MediSetter Interview: Insight on Opportunities in Asia's Healthcare Industry

Introduction to MedisetterI had the pleasure of interviewing Anirban Lahiri of Medisetter to discuss some of the opportunities present in Asia's...

Nomadic Equity

SillaJen's December IPO: Valuation, Growth Expectation and IPO Timing

SillaJen Biotherapeutics (established in 2006) is indeed a rare breed in Korean pharmaceutical world. It is not a generic drug maker. It is not a...

Sanghyun Park

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)